vs
CareDx, Inc.（CDNA）与GRAIL, Inc.（GRAL）财务数据对比。点击上方公司名可切换其他公司
CareDx, Inc.的季度营收约是GRAIL, Inc.的2.5倍（$108.4M vs $43.6M）。CareDx, Inc.净利率更高（-3.8% vs -227.5%，领先223.7%）。CareDx, Inc.同比增速更快（25.2% vs 14.0%）。过去两年GRAIL, Inc.的营收复合增速更高（27.7% vs 22.7%）
CareDx是一家专注于器官移植领域的精准医疗企业，核心产品包括移植排斥反应监测诊断试剂、数字健康管理工具及配套临床服务，面向北美和欧洲市场的医疗机构及移植患者，助力提升术后患者生存质量。
GRAIL是2015年成立的美国生物技术企业，总部位于加利福尼亚州门洛帕克，核心业务是研发面向无症状人群的癌症早期筛查检测产品。该公司最初是基因测序企业Illumina旗下的初创子公司，2021年被Illumina全资收购。
CDNA vs GRAL — 直观对比
营收规模更大
CDNA
是对方的2.5倍
$43.6M
营收增速更快
CDNA
高出11.2%
14.0%
净利率更高
CDNA
高出223.7%
-227.5%
两年增速更快
GRAL
近两年复合增速
22.7%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $108.4M | $43.6M |
| 净利润 | $-4.1M | $-99.2M |
| 毛利率 | — | — |
| 营业利润率 | -5.6% | -285.4% |
| 净利率 | -3.8% | -227.5% |
| 营收同比 | 25.2% | 14.0% |
| 净利润同比 | -104.7% | -2.2% |
| 每股收益（稀释后） | $-0.08 | $-2.37 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CDNAGRAL
| Q4 25 | $108.4M | $43.6M | ||
| Q3 25 | $100.1M | $36.2M | ||
| Q2 25 | $86.7M | $35.5M | ||
| Q1 25 | $84.7M | $31.8M | ||
| Q4 24 | $86.6M | $38.3M | ||
| Q3 24 | $82.9M | $28.7M | ||
| Q2 24 | $92.3M | $32.0M | ||
| Q1 24 | $72.0M | $26.7M |
净利润CDNAGRAL
| Q4 25 | $-4.1M | $-99.2M | ||
| Q3 25 | $1.7M | $-89.0M | ||
| Q2 25 | $-8.6M | $-114.0M | ||
| Q1 25 | $-10.4M | $-106.2M | ||
| Q4 24 | $87.7M | $-97.1M | ||
| Q3 24 | $-10.6M | $-125.7M | ||
| Q2 24 | $-4.6M | $-1.6B | ||
| Q1 24 | $-19.9M | $-218.9M |
营业利润率CDNAGRAL
| Q4 25 | -5.6% | -285.4% | ||
| Q3 25 | -0.2% | -346.2% | ||
| Q2 25 | -12.8% | -446.9% | ||
| Q1 25 | -15.8% | -482.5% | ||
| Q4 24 | 97.5% | -358.0% | ||
| Q3 24 | -16.6% | -640.5% | ||
| Q2 24 | -7.9% | -5133.8% | ||
| Q1 24 | -31.3% | -851.1% |
净利率CDNAGRAL
| Q4 25 | -3.8% | -227.5% | ||
| Q3 25 | 1.7% | -245.8% | ||
| Q2 25 | -9.9% | -320.7% | ||
| Q1 25 | -12.2% | -333.6% | ||
| Q4 24 | 101.3% | -253.8% | ||
| Q3 24 | -12.8% | -438.7% | ||
| Q2 24 | -5.0% | -4958.8% | ||
| Q1 24 | -27.6% | -819.3% |
每股收益（稀释后）CDNAGRAL
| Q4 25 | $-0.08 | $-2.37 | ||
| Q3 25 | $0.03 | $-2.46 | ||
| Q2 25 | $-0.16 | $-3.18 | ||
| Q1 25 | $-0.19 | $-3.10 | ||
| Q4 24 | $1.60 | $-1.49 | ||
| Q3 24 | $-0.20 | $-3.94 | ||
| Q2 24 | $-0.09 | $-51.06 | ||
| Q1 24 | $-0.38 | $-7.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $177.2M | $249.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $303.1M | $2.6B |
| 总资产 | $413.2M | $2.9B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CDNAGRAL
| Q4 25 | $177.2M | $249.7M | ||
| Q3 25 | $194.2M | $126.9M | ||
| Q2 25 | $186.3M | $127.4M | ||
| Q1 25 | $230.9M | $133.9M | ||
| Q4 24 | $260.7M | $214.2M | ||
| Q3 24 | $240.9M | $853.6M | ||
| Q2 24 | $228.9M | $958.8M | ||
| Q1 24 | $215.9M | $199.7M |
总债务CDNAGRAL
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $0 | — | ||
| Q2 24 | $0 | — | ||
| Q1 24 | — | — |
股东权益CDNAGRAL
| Q4 25 | $303.1M | $2.6B | ||
| Q3 25 | $311.1M | $2.2B | ||
| Q2 25 | $327.4M | $2.3B | ||
| Q1 25 | $379.3M | $2.4B | ||
| Q4 24 | $378.4M | $2.5B | ||
| Q3 24 | $273.2M | $2.6B | ||
| Q2 24 | $264.7M | $2.7B | ||
| Q1 24 | $256.2M | — |
总资产CDNAGRAL
| Q4 25 | $413.2M | $2.9B | ||
| Q3 25 | $432.3M | $2.6B | ||
| Q2 25 | $444.3M | $2.7B | ||
| Q1 25 | $489.6M | $2.8B | ||
| Q4 24 | $491.1M | $3.0B | ||
| Q3 24 | $477.0M | $3.1B | ||
| Q2 24 | $466.8M | $3.3B | ||
| Q1 24 | $452.4M | — |
负债/权益比CDNAGRAL
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.00× | — | ||
| Q2 24 | 0.00× | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $21.4M | $-63.8M |
| 自由现金流经营现金流 - 资本支出 | — | $-63.9M |
| 自由现金流率自由现金流/营收 | — | -146.5% |
| 资本支出强度资本支出/营收 | — | 0.2% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-299.9M |
8季度趋势，按日历期对齐
经营现金流CDNAGRAL
| Q4 25 | $21.4M | $-63.8M | ||
| Q3 25 | $37.4M | $-63.2M | ||
| Q2 25 | $9.9M | $-77.0M | ||
| Q1 25 | $-26.6M | $-95.0M | ||
| Q4 24 | $21.9M | — | ||
| Q3 24 | $12.5M | $-104.6M | ||
| Q2 24 | $18.9M | $-171.8M | ||
| Q1 24 | $-15.3M | $-207.3M |
自由现金流CDNAGRAL
| Q4 25 | — | $-63.9M | ||
| Q3 25 | — | $-63.6M | ||
| Q2 25 | — | $-77.3M | ||
| Q1 25 | — | $-95.1M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-105.6M | ||
| Q2 24 | — | $-173.2M | ||
| Q1 24 | — | $-209.8M |
自由现金流率CDNAGRAL
| Q4 25 | — | -146.5% | ||
| Q3 25 | — | -175.8% | ||
| Q2 25 | — | -217.6% | ||
| Q1 25 | — | -298.6% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -368.4% | ||
| Q2 24 | — | -541.7% | ||
| Q1 24 | — | -785.3% |
资本支出强度CDNAGRAL
| Q4 25 | — | 0.2% | ||
| Q3 25 | — | 1.1% | ||
| Q2 25 | — | 1.0% | ||
| Q1 25 | — | 0.2% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 3.4% | ||
| Q2 24 | — | 4.3% | ||
| Q1 24 | — | 9.5% |
现金转化率CDNAGRAL
| Q4 25 | — | — | ||
| Q3 25 | 22.30× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.25× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CDNA
| Services | $78.4M | 72% |
| Patient And Digital Solutions | $16.8M | 15% |
| Products | $13.3M | 12% |
GRAL
| Screening Revenue | $42.3M | 97% |
| Developmental Services Revenue | $1.3M | 3% |
